What is Recurrent Anal Cancer?
Recurrent anal cancer refers to cancer that has returned after initial treatment. It can reappear in or near the same area (local recurrence), in nearby lymph nodes (regional recurrence), or in distant organs such as the lungs, liver, or bones (distant recurrence).
If your cancer returns, your medical team will conduct tests to determine its stage and location. The treatment approach depends on previous treatments received and the site of recurrence. Learn more about living with anal cancer to understand treatment side effects and management strategies.
What is Advanced Anal Cancer (Stage IV)?
Advanced anal cancer, or stage IV anal cancer, occurs when cancer has spread beyond the anus to distant organs, such as the lungs, liver, brain, or bones. This happens when cancerous cells travel through the lymphatic system or bloodstream, forming new tumours elsewhere in the body.
The preferred regimen for first-line treatment of metastatic anal cancer is carboplatin + paclitaxel + retifanlimab-dwlr. Learn more about treatment for anal cancer to explore available options.
Chemotherapy
Chemotherapy is the primary treatment for both recurrent and advanced anal cancer. The standard regimen typically includes 5-fluorouracil (5-FU) and cisplatin, sometimes combined with other drugs like paclitaxel or carboplatin. Immunotherapy drugs, such as nivolumab and pembrolizumab, may also be recommended for patients whose cancer has not responded to first-line treatments.
Radiation Therapy
Radiation therapy is sometimes used alongside chemotherapy, particularly in cases of local or regional recurrence. For some patients, radiation may be combined with radiosensitizing agents to enhance its effectiveness.
Clinical Trials
Clinical trials offer patients access to new and potentially more effective treatments for recurrent and advanced anal cancer. These trials study various approaches, including targeted therapies, immunotherapies, and new chemotherapy combinations.
Radiosensitizing Agents
Radiosensitizing agents make tumors more sensitive to radiation, potentially allowing for lower radiation doses while maintaining effectiveness. Clinical trials are evaluating these drugs to improve outcomes and reduce treatment-related side effects.
Surgery Improvements
Surgical advances are being explored for recurrent anal cancer, particularly for patients undergoing an abdominoperineal resection (APR). Research is also examining the use of artificial bowel sphincters to improve post-surgical quality of life.
Targeted Drugs
Targeted therapies focus on specific genetic changes within cancer cells. Some drugs aim to block the epidermal growth factor receptor (EGFR), which is often overexpressed in anal cancer. These treatments may be beneficial when chemotherapy is ineffective and may result in fewer side effects.
Immunotherapy
Immunotherapy boosts the body’s natural defences to fight cancer. In the United States, a new treatment called retifanlimab-dwlr (retifanlimab) has recently been approved by the FDA for some people with advanced anal cancer.
Retifanlimab blocks a protein called PD-1, which cancer cells use to ‘hide’ from the immune system. By blocking this protein, the immune system can better recognise and fight the cancer.
Retifanlimab can be used in two ways:
- With chemotherapy for adults with inoperable locally recurrent or metastatic anal cancer who have never had chemotherapy before.
- As a single agent for adults whose cancer has progressed or who cannot tolerate platinum-based chemotherapy
Studies have shown that adding retifanlimab to chemotherapy helps control the cancer for longer and leads to more tumour shrinkage. When used alone, it can also help some patients whose cancer has already returned or progressed.
Other immunotherapies including nivolumab and pembrolizumab may also be options if the cancer does not respond to earlier treatments. Vaccine-based immunotherapies are also being explored for HPV-related cancers, including anal cancer.
Clinical Trials for US Patients
Patients in the US can search for ongoing clinical trials through ClinicalTrials.gov and the National Cancer Institute (NCI) clinical trial database. These resources provide information on eligibility criteria, study locations, and trial objectives.
Clinical Trials for UK Patients
In the UK, clinical trials are listed on the NHS clinical trials database. Speak to your doctor about suitable trials and eligibility requirements.
Genome Research
Genome research is revolutionizing cancer treatment by identifying genetic mutations that drive cancer growth. Scientists compare the DNA of healthy and cancerous cells to find differences that can be targeted with personalized therapies.
Some hospitals now offer genetic testing of tumor samples to determine whether targeted treatments may be effective. However, this testing is not yet standard for anal cancer, and availability may vary.
Projects like The Cancer Genome Atlas (TCGA) in the US and the 100,000 Genomes Project in the UK are working to advance our understanding of cancer genetics. While HPV-related cancers are not yet a primary focus, research in this area is expanding.
To learn more about the future of anal cancer treatment, visit our Research Roadmap.
If you are looking for support, our Peer-to-Peer Support Programme connects patients with others who understand their journey. Register now to speak with someone who has been through a similar experience.
What is Recurrent Anal Cancer?
Recurrent anal cancer refers to cancer that has returned after initial treatment. It can reappear in or near the same area (local recurrence), in nearby lymph nodes (regional recurrence), or in distant organs such as the lungs, liver, or bones (distant recurrence).
If your cancer returns, your medical team will conduct tests to determine its stage and location. The treatment approach depends on previous treatments received and the site of recurrence. Learn more about living with anal cancer to understand treatment side effects and management strategies.
What is Advanced Anal Cancer (Stage IV)?
Advanced anal cancer, or stage IV anal cancer, occurs when cancer has spread beyond the anus to distant organs, such as the lungs, liver, brain, or bones. This happens when cancerous cells travel through the lymphatic system or bloodstream, forming new tumours elsewhere in the body.
The standard treatment for advanced anal cancer includes chemotherapy, often combined with radiation therapy. Learn more about treatment for anal cancer to explore available options.
Chemotherapy
Chemotherapy is the primary treatment for both recurrent and advanced anal cancer. The standard regimen typically includes 5-fluorouracil (5-FU) and cisplatin, sometimes combined with other drugs like paclitaxel or carboplatin. Immunotherapy drugs, such as nivolumab and pembrolizumab, may also be recommended for patients whose cancer has not responded to first-line treatments.
Radiation Therapy
Radiation therapy is sometimes used alongside chemotherapy, particularly in cases of local or regional recurrence. For some patients, radiation may be combined with radiosensitizing agents to enhance its effectiveness.
Clinical Trials
Clinical trials offer patients access to new and potentially more effective treatments for recurrent and advanced anal cancer. These trials study various approaches, including targeted therapies, immunotherapies, and new chemotherapy combinations.
Radiosensitizing Agents
Radiosensitizing agents make tumors more sensitive to radiation, potentially allowing for lower radiation doses while maintaining effectiveness. Clinical trials are evaluating these drugs to improve outcomes and reduce treatment-related side effects.
Surgery Improvements
Surgical advances are being explored for recurrent anal cancer, particularly for patients undergoing an abdominoperineal resection (APR). Research is also examining the use of artificial bowel sphincters to improve post-surgical quality of life.
Targeted Drugs
Targeted therapies focus on specific genetic changes within cancer cells. Some drugs aim to block the epidermal growth factor receptor (EGFR), which is often overexpressed in anal cancer. These treatments may be beneficial when chemotherapy is ineffective and may result in fewer side effects.
Immunotherapy
Immunotherapy boosts the body’s natural defences to fight cancer. Current research is investigating checkpoint inhibitors like nivolumab, which help the immune system recognize and attack cancer cells. Vaccine-based immunotherapies are also being explored for HPV-related cancers, including anal cancer.
Clinical Trials for US Patients
Patients in the US can search for ongoing clinical trials through ClinicalTrials.gov and the National Cancer Institute (NCI) clinical trial database. These resources provide information on eligibility criteria, study locations, and trial objectives.
Clinical Trials for UK Patients
In the UK, clinical trials are listed on the NHS clinical trials database. Speak to your doctor about suitable trials and eligibility requirements.
Genome Research
Genome research is revolutionizing cancer treatment by identifying genetic mutations that drive cancer growth. Scientists compare the DNA of healthy and cancerous cells to find differences that can be targeted with personalized therapies.
Some hospitals now offer genetic testing of tumor samples to determine whether targeted treatments may be effective. However, this testing is not yet standard for anal cancer, and availability may vary.
Projects like The Cancer Genome Atlas (TCGA) in the US and the 100,000 Genomes Project in the UK are working to advance our understanding of cancer genetics. While HPV-related cancers are not yet a primary focus, research in this area is expanding.
To learn more about the future of anal cancer treatment, visit our Research Roadmap.
If you are looking for support, our Peer-to-Peer Support Programme connects patients with others who understand their journey. Register now to speak with someone who has been through a similar experience.
Share this: on Twitter on Facebook
